Atara Biotherapeutics (ATRA) Net Margin (2022 - 2026)
Atara Biotherapeutics (ATRA) reported Net Margin of 803.29% for Q1 2026, down 84202.0% on a YoY basis from N/an in Q1 2025, and up 64.55% quarter-over-quarter from 2266.02% in Q4 2025.
Atara Biotherapeutics (ATRA) Net Margin (2022 - 2026) Analysis & Trends
Atara Biotherapeutics has reported Net Margin for 5 years, with the latest figure at 803.29% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin fell 84202.0% year-over-year to 803.29%; the trailing twelve-month figure through Mar 2026 stood at 182.39% (down 17456.0% YoY), and the FY2025 full-year result was 0.04%, up 6619.0% from the prior year.
- Net Margin for Q1 2026 stood at 803.29%, up from 2266.02% in the prior quarter.
- The five-year high for Net Margin was 38.73% in Q1 2025, with the low at 33790.5% in Q4 2022.
- Historically, Net Margin has averaged 3622.0% across 5 years, with a median of 463.96% in 2026.
- The largest YoY upside for Net Margin was 3254565 bps in 2023 against a maximum downside of 900276 bps in 2023.
- Atara Biotherapeutics' Net Margin stood at 33790.5% in 2022, then surged by 96 bps to 1244.85% in 2023, then jumped by 97 bps to 38.75% in 2024, then plunged by 5747 bps to 2266.02% in 2025, then surged by 65 bps to 803.29% in 2026.
- The last three Net Margin figures came in at 803.29% (Q1 2026), 2266.02% (Q4 2025), and 124.62% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 0.82% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Atara Biotherapeutics | 134.61 Mn | 126.21 Mn | 392,000.00 | -803.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -803.29% |
| Dec 31, 2025 | -2,266.02% |
| Sep 30, 2025 | -124.62% |
| Jun 30, 2025 | 13.58% |
| Mar 31, 2025 | 38.73% |
| Dec 31, 2024 | -38.75% |
| Sep 30, 2024 | -54.51% |
| Jun 30, 2024 | -66.51% |
| Mar 31, 2024 | -116.07% |
| Dec 31, 2023 | -1,244.85% |
| Sep 30, 2023 | -3,264.59% |
| Jun 30, 2023 | -8,966.96% |
| Mar 31, 2023 | -6,098.78% |
| Dec 31, 2022 | -33,790.50% |
| Jun 30, 2022 | 35.80% |
| Mar 31, 2022 | -1,204.61% |